Economic Analysis of Alemtuzumab (MabCampath®) in Fludarabinerefractory Chronic Lymphocytic Leukemia

N. Mittmann*, 1, P. K. Isogai1, J. M. Connors2, M. Rebeira3, M. C. Cheung4
1 Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
2 Centre for Lymphoid Cancer, BC Cancer Agency and the University of British Columbia, British Columbia, Canada
3 Genzyme Canada Inc., Mississauga, Canada 4Division of Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1422
Abstract HTML Views: 2332
PDF Downloads: 320
Total Views/Downloads: 4074
Unique Statistics:

Full-Text HTML Views: 696
Abstract HTML Views: 1233
PDF Downloads: 242
Total Views/Downloads: 2171

© Mittmann et al.;

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, E240, Toronto, Ontario M4N 3M5, Canada. Tel: 416-480-6100, Ext. 1652; Fax: 416-480- 6025; E-mail:



The objective of this economic analysis is to determine the cost-effectiveness of alemtuzumab in the treatment of B cell chronic lymphocytic leukemia (B-CLL) patients who have progressed despite fludarabine therapy.


This model was developed according to the Canadian public payer health system considering only direct medical costs. Effectiveness information was obtained from the published literature. Resource utilization was based on guidelines, literature and expert opinion. Cost information was obtained from provincial costing sources and presented in 2008 Canadian dollars. The primary comparators for this analysis were alemtuzumab, Various Treatments (VT) (combination of agents), fludarabine+cyclophosphamide (FC), fludarabine+cyclophosphamide+rituximab (FCR) and best supportive care (BSC).


Estimated mean survival for alemtuzumab was 22.68 months (1.89 years). Mean survival for VT was estimated from the literature at 16.32 months (1.36 years). The mean survival for FC was 17.44 months (1.45 years) and FCR 20.06 months (1.67 years). The incremental cost-effectiveness ratio (ICER) for alemtuzumab vs VT was $43,615/life year gained (LYG); $52,536/LYG for the alemtuzumab vs FC; $21,818/LYG vs FCR; and less costly and more effective vs BSC. ICERs were sensitive to three variables: treatment duration of alemtuzumab; treatment duration of FCR; and additional survival due to rituximab for FCR patients compared to FC.


The results showed that the ICERs for alemtuzumab in B-CLL patients who have failed fludarabine ranged from $21,818/LYG to $52,536/LYG compared to active treatment, and was less costly and more efficacious compared to BSC.

Keywords: Alemtuzumab, chronic lymphocytic leukemia, cost-effectiveness, economic analysis, fludarabine.